Skip to main content
SpringerLink
Log in

Classification of Tumours of the Central Nervous System

  • Chapter
  • First Online:
Neurorehabilitation in Neuro-Oncology

Abstract

CNS tumours include both primary and secondary neoplasms. The diagnostic criteria of primary CNS tumours have been significantly updated by the latest WHO classification (Fourth Edition, Revised), published in 2016. Molecular parameters, which were previously considered as supplementary information, are now used to define CNS tumours by employing an integrated histological–molecular classification. This novel approach allowed to define specific entities which are more consistent in terms of phenotypical, genotypical and clinical characteristics, compared to the previous criteria which were based on histopathological findings alone. Diffuse gliomas are a paradigmatic example of this novel approach: the newly introduced classification, which is mainly based on two molecular alterations (IDH1/IDH2 mutation and 1p/19q codeletion), allows to recognize specific prognostically relevant entities, despite possible morphological ambiguities. These changes will hopefully help provide the best case possible to patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-Oncology. 2016;18(Suppl_5):v1–v75. https://doi.org/10.1093/neuonc/now207.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Louis DN. International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. Revised 4th ed. World Health Organization classification of tumours. Lyon: International Agency For Research On Cancer; 2016.

    Google Scholar 

  3. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–73. https://doi.org/10.1007/s00401-015-1438-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hubner JM, Kool M, Pfister SM, Pajtler KW. Epidemiology, molecular classification and WHO grading of ependymoma. J Neurosurg Sci. 2017; https://doi.org/10.23736/S0390-5616.17.04152-2.

  5. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology. 2016;18(1):16–26. https://doi.org/10.1093/neuonc/nov136.

    Article  CAS  PubMed  Google Scholar 

  6. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, et al. Telomere maintenance and the etiology of adult glioma. Neuro-Oncology. 2015;17(11):1445–52. https://doi.org/10.1093/neuonc/nov082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. LeBlanc VG, Marra MA. DNA methylation in adult diffuse gliomas. Brief Funct Genomics. 2016; https://doi.org/10.1093/bfgp/elw019.

  9. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407–17. https://doi.org/10.1007/s00401-015-1454-8.

    Article  CAS  PubMed  Google Scholar 

  10. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50. https://doi.org/10.1200/JCO.2012.43.2229.

    Article  CAS  PubMed  Google Scholar 

  11. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43. https://doi.org/10.1200/JCO.2012.43.2674.

    Article  CAS  PubMed  Google Scholar 

  12. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. https://doi.org/10.1016/S1470-2045(09)70025-7.

    Article  CAS  PubMed  Google Scholar 

  13. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146–57. https://doi.org/10.1158/1078-0432.CCR-13-0017.

    Article  CAS  PubMed  Google Scholar 

  14. Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol. 2010;34(2):147–60. https://doi.org/10.1097/PAS.0b013e3181c75238.

    Article  PubMed  Google Scholar 

  15. Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A, et al. Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery. 2003;53(3):544–53. discussion 54–5

    Article  PubMed  Google Scholar 

  16. Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, et al. Pleomorphic Xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25(5):575–86. https://doi.org/10.1111/bpa.12217.

    Article  CAS  PubMed  Google Scholar 

  17. de Ribaupierre S, Dorfmuller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60(1):83–9.; discussion 9–90. https://doi.org/10.1227/01.NEU.0000249216.19591.5D.

    Article  PubMed  Google Scholar 

  18. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–43. https://doi.org/10.1016/j.ccell.2015.04.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. 2014;506(7489):451–5. https://doi.org/10.1038/nature13109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011;10:7. https://doi.org/10.1186/1477-5751-10-7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013;23(5):574–83. https://doi.org/10.1111/bpa.12048.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-Oncology. 2010;12(7):621–30. https://doi.org/10.1093/neuonc/noq007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405. https://doi.org/10.1007/s00401-011-0802-6.

    Article  CAS  PubMed  Google Scholar 

  24. Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer. 2004;101(1):146–55. https://doi.org/10.1002/cncr.20332.

    Article  PubMed  Google Scholar 

  25. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M. Tumor recurrence and malignant progression of gangliogliomas. Cancer. 2008;113(12):3355–63. https://doi.org/10.1002/cncr.23965.

    Article  PubMed  Google Scholar 

  26. Karremann M, Pietsch T, Janssen G, Kramm CM, Wolff JE. Anaplastic ganglioglioma in children. J Neuro-Oncol. 2009;92(2):157–63. https://doi.org/10.1007/s11060-008-9747-6.

    Article  Google Scholar 

  27. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–84. https://doi.org/10.1007/s00401-012-0958-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31(23):2927–35. https://doi.org/10.1200/JCO.2012.48.5052.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121(3):381–96. https://doi.org/10.1007/s00401-011-0800-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120(2):253–60. https://doi.org/10.1007/s00401-010-0688-8.

    Article  PubMed  Google Scholar 

  31. Nobusawa S, Yokoo H, Hirato J, Kakita A, Takahashi H, Sugino T, et al. Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol. 2012;22(5):689–97. https://doi.org/10.1111/j.1750-3639.2012.00574.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol. 2015;16(5):569–82. https://doi.org/10.1016/S1470-2045(15)70114-2.

    Article  CAS  PubMed  Google Scholar 

  33. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell. 2016;29(3):379–93. https://doi.org/10.1016/j.ccell.2016.02.001.

    Article  CAS  PubMed  Google Scholar 

  34. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 2017;133(1):1–3. https://doi.org/10.1007/s00401-016-1646-x.

    Article  PubMed  Google Scholar 

  35. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017;27(6):851–2. https://doi.org/10.1111/bpa.12457.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pathology, Department of Medical Sciences, University of Turin, Turin, Italy

    Luca Bertero & Paola Cassoni

Authors
  1. Luca Bertero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Cassoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Bertero .

Editor information

Editors and Affiliations

  1. Department of Rehabilitation, Neurorehabilitation Unit, Habilita S.p.A., Zingonia/Ciserano, Bergamo, Italy

    Michelangelo Bartolo

  2. University and City of Health and Science, Department Neuro-Oncology, Turin, Torino, Italy

    Riccardo Soffietti

  3. Department of Medical Psychology, VU University Medical Center Department of Medical Psychology, Amsterdam, The Netherlands

    Martin Klein

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bertero, L., Cassoni, P. (2019). Classification of Tumours of the Central Nervous System. In: Bartolo, M., Soffietti, R., Klein, M. (eds) Neurorehabilitation in Neuro-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95684-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95684-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95683-1

  • Online ISBN: 978-3-319-95684-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation